MAVENCLAD™ (cladribine tablets) │ EMD Serono
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.

{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

3-month EDSS progression


Time to 3-month EDSS progression (secondary endpoint)2*

 EDSS Progression  EDSS Progression

Learn more about MAVENCLAD


Demonstrated reduction in ARR

Relapse-free rate

Demonstrated reduction in brain lesions



See how MAVENCLAD achieved
a 57.6% relative reduction in ARR over 96 weeks vs. placebo
(p<0.001, 0.14 vs. 0.33, respectively). 

Learn more

See how MAVENCLAD allowed
79.7% of patients to remain relapse-free
at 96 weeks (vs. placebo, 79.7 vs. 60.9, respectively; p<0.001; secondary endpoint).

Learn more

Discover how MAVENCLAD
demonstrated an 86% relative
reduction in T1 Gd+ lesions and 73% in T2 lesions over 96 weeks
vs. placebo (p<0.001; mean lesions:
T1 Gd+, 0.12 vs. 0.91; T2,  0.38 vs. 1.43; secondary endpoint).

Learn more

Footnotes and References

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing

* 96-week, phase III, multicentre, double-blind, placebo-controlled trial to evaluate the safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis. 1,326 patients were randomized (1:1:1) to receive a cumulative dose of cladribine tablets (3.5 mg/kg [n=433] or 5.25 mg/kg [n=456]) or placebo (n=437), in two treatment courses. The 5.25 mg/kg dosage regimen is not available.1

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.